- Japan's Ministry of Health, Labour and Welfare has approved Legend Biotech's ( NASDAQ: LEGN ) Carvykti (ciltacabtagene autoleucel) for relapsed/refractory multiple myeloma.
- The New Drug Application in the country was submitted by Legend's ( LEGN ) partner, Johnson & Johnson's ( JNJ ) Janssen unit.
- The approval is based on data from the phase 1b/2 CARTITUDE-1 study, and included patients who received a median of six prior treatments.
- Seeking Alpha's Quant Rating views Legend ( LEGN ) as a hold with high marks for growth and momentum .
For further details see:
Legend Biotech wins approval of Carvykti for multiple myeloma in Japan